Cancer-associated fibroblasts drive metabolic heterogeneity in KRAS-mutant colorectal cancer cells

KRAS-mutant colorectal cancer (CRC) is characterized by metabolic reprogramming that can lead to tumor progression and drug resistance. The tumor microenvironment (TME) plays a pivotal role in modulating these metabolic adaptations. In particular, cancer-associated fibroblasts (CAFs), which make up a large portion of the TME, have been shown to strongly contribute to metabolic reprogramming in CRC. This study applies flux sampling, a computational method that explores the full range of feasible metabolic states, combined with representation learning and hierarchical clustering, to a computational model of central carbon metabolism to understand how CAFs influence metabolic adaptations of KRAS-mutant CRC cells following targeted enzyme knockdowns. Focusing on twelve key enzymes involved in glycolysis and the pentose phosphate pathway, knockdowns were simulated under both normal CRC media and CAF-conditioned media (CCM) conditions. Analysis revealed that CCM induces greater metabolic heterogeneity, with knockdown models exhibiting more variable and distinct metabolic states compared to those cultured in normal CRC media. While some enzyme knockdowns produced similar metabolic states, this overlap was less frequent in CCM, indicating that CAF-derived factors diversify the metabolic responses of CRC cells to enzyme perturbations. Pathway-level flux analysis demonstrated media-specific shifts in central carbon metabolism pathways. Importantly, the predicted biomass flux showed that enzyme knockdowns reduced growth across both conditions, but models in the CCM condition indicated CAFs could offer a protective effect against metabolic perturbation. Overall, this study reveals that CCM significantly influences the metabolic state and adaptability of KRAS-mutant CRC cells to enzyme perturbations, emphasizing the importance of including TME components in metabolic modeling and therapeutic development. These findings provide valuable insights into the metabolic adaptability of CRC and suggest that targeting tumor-CAF metabolic interactions may improve treatment strategies.